A sodium-glucose cotransporter 2 (SGLT2) inhibitor with proven benefit for the specific comorbidity is recommended in multiple guidelines, including those from the American Diabetes Association and in Canadian guidelines as part of the glucose-lowering regimen for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high risk, established kidney disease, or heart failure. Multiple clinical trials have demonstrated the beneficial effects of SGLT2 inhibitors, including the EMPEROR-Reduced Clinical trial where empagliflozin was shown to reduce the risk for cardiovascular death by 38% and decline in GFR.
To date, there has been no evidence of similar cardiovascular or renal benefits of lowering glucose using older therapies indicated for patients with type 2 diabetes, such as metformin, sulfonylureas, thiazolidinediones, or insulin, or for the newer dipeptidyl peptidase 4 inhibitors.
Learn more about cardiovascular risk management in type 2 diabetes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Fast Five Quiz: Glycemic Control in Type 2 Diabetes - Medscape - Feb 21, 2023.